
# Health and Justice AMS Update


Naomi Fleming


## Overall antibiotic prescribing per 100 prisoners is falling (4% drop since Apr 24)



## Broad spectrum trend

Broad spectrum as % of total antibiotic prescribing is climbing but has levelled at around 13%- mainly due to co-amoxiclav





#### 'Let's talk about co-amoxiclav' document to share with clinicians, laminated as a poster or used as a screen saver.

Let's talk about co-amoxiclav: (please adopt/adapt for your setting eg A+E, urgent care, health and justice, CHS, MHS, primary care)

- Co-amoxiclav is useful where broad spectrum cover is needed for Gram-positive, Gram-negative and anaerobic bacteria.
- This cover is needed for intra-abdominal infections, for animal/human bites or for 'dirty' contaminated wounds. It is not needed for insect bites or clean wounds
- Co-amoxiclav only has limited recommendations in NICE guidelines. <u>Products Antimicrobial stewardship | Topic | NICE</u>
- As resistance to co-amoxiclav in E. coli is rising, it is no longer first line for pyelonephritis/upper UTI
- Co-amoxiclay is one of the antibiotics most associated with C difficile, which is on the increase across the UK.
- Use first line empirical options, for optimum course lengths to prevent resistance and adverse effects.

Common infection	Likely bacteria	Empirical Options	Duration	Should I use co-amoxiclay?
Acute otitis media	Strep. pneumoniae Haemophilus influenzae	Otico" ear drops Only if antibiotics needed: Amoxicillin OR Clarithromycin	5 days	Only in case of treatment failure (no improvement with 2-3 days of first line antibiotics)
Respiratory CAP (CRB-65 0-2)	Strep. pneumoniae Haemophilus influenzae	Amoxicitlin OR Doxycycline OR Co-trimoxazole	5 days adults, 3 days children	No, unless previous resistance to first line antibiotics or CRB-65 3-4
Respiratory (Aspiration)	Strep. pneumoniae Haemophilus influenzae E. coti, Enterobacteriaceae Bacteroides fragilis	Amoxicitlin +/- metronidazole OR Doxycycline +/- metronidazole OR Co-trimoxazole +/- metronidazole	5 days	No, unless treatment failure
Respiratory (acute exacerbation of COPD)	Strep pneumoniae Haemophilus influenzae Moraxella catarrhalis	Amoxicitiin OR Doxycycline OR Co-trimoxazole	5 days	If at risk of treatment failure eg resistance or adverse effects to all first line antibiotics
Sinusitis	B haemolytic strep. (A.B.C.G)  Strep. pneumoniae  Haemophilus influenzae  Bacteroides fragilis	High dose nasal steroid  Only if antibiotics needed:  Phenoxymethylpenicillin OR  Doxycycline	5 days	If systemically very unwell or high risk of complications
Skin and soft tissue infections, including insect bites and leg ulcers (not diabetic foot, cellulitis with vascular deficiency or burns)	Staph. aureus β haemolytic strep. ( <u>A.B.C.G</u> )	Fluctoxacitlin OR Doxycycline	5-7 days	No, unless 'dirty' contaminated wound eg faecal matter, soil OR if infection near eyes or nose
Urinary tract infection (lower)	E. coli Enterobacteriaceae	Nitrofurantoin OR Eixposittioan	3 days women, 7 days men	No
Upper urinary tract infection (pyelonephritis)	E. coli Enterobacteriaceae	Cefatexin OR Trimethoprim (only if culture results available and susceptible)	7 days	Only if culture results available and susceptible
Dental infections (As an adjunct to dental treatment ONLY if evidence of systemic spread or diffuse swelling)	Oral strep. Oral anaerobes	Phenoxymethylpenicillin OR Amoxicillin OR Metronidazole	5 days	Only on advice of a microbiologist or infectious disease specialist
Animal/human bite	Staph. Aureus, β haemolytic strep. ( <u>A.B.C.G</u> ) Haemophitus influenzae Bacteroides fragilis, Clostridium perfringens	Co-amoxiclay OR Doxycyctine <b>plus</b> metronidazole OR Co-trimoxazole	3 days prophylaxis, 5 days treatment	Yes, one of the first line options
Diverticulitis/ cholangitis/cholecystitis	Enterococcus faecalis, Enterococcus faecium, E. coli, Enterobacteriaceaa, Bacteroides fragilis, Clostridium perfringens	Co-amoxiclay OR Cefalexin plus metronidazole OR Trimethoprim plus metronidazole	5 days	Yes, one of the first line options

Co-amoxiclav is useful where broad spectrum cover is needed for Grampositive, Gram -negative and anaerobic bacteria. This cover is needed for intra-abdominal infections, for animal/human bites or for 'dirty' contaminated wounds. It is not needed for insect bites or clean wounds. Co-amoxiclav only has limited recommendations in NICE guidelines. Products - Antimicrobial stewardship | Topic | NICE . As resistance to co-amoxiclav in *E. coli* is rising, it is no longer first line for pyelonephritis/upper UTI.

Use first line empirical options, for optimum course lengths to prevent resistance and adverse effects. (Co-amoxiclav is one of the antibiotics most associated with *C* difficile, which is on the increase across the UK).

## Top 10 antibiotics and sites (Apr 25 to Sep 25)

Top 10 Sites by Volume			
Site	No of		
Site	Prescriptions		
HMP PETERBOROUGH	1174		
HMP HOLME HOUSE	1148		
HMP/ YOI DONCASTER	1095		
HMP WANDSWORTH	1073		
HMP/ YOI FOREST BANK	1032		
HMP BIRMINGHAM	1017		
HMP LEEDS	955		
HMP THAMESIDE	950		
HMP ALTCOURSE	914		
HMP WORMWOOD SCRUBS	895		

Top 10 Drugs				
Drug	No of Prescriptions			
Flucloxacillin	10278			
Amoxicillin	7487			
Doxycycline	5847			
Co-amoxiclav	5265			
Lymecycline	3688			
Metronidazole	3069			
Clarithromycin	2446			
Phenoxymethylpenicillin	2358			
Nitrofurantoin	1745			
Fusidic acid	1534			

#### Men

#### Top 10 Sites by per 100 head Population No of Site Prescriptions HMP/YOI FELTHAM 0.63 HMP GRENDON & SPRINGHILL 0.54 HMP KIRKLEVINGTON GRANGE 0.42 0.38 HMYOI WARREN HILL 0.31 HMP NORTH SEA CAMP 0.25 HMP SPRING HILL HMYOI HATFIELD 0.24 HMP ASHFIELD 0.23 0.23 HMP FORD HMYOI AYLESBURY 0.23

#### Women

Top 10 Sit	es by per 1	100 head I	Population

Site	No of	
Site	Prescriptions	
HMP/ YOI ASKHAM GRANGE	1.09	
HMP/ YOI EAST SUTTON PARK	1.05	
HMP SEND	0.37	
HMP LOW NEWTON	0.29	
HMP/ YOI DRAKE HALL	0.27	
HMP DOWNVIEW	0.27	
HMP/ YOI NEW HALL	0.24	
HMP/YOI FOSTON HALL	0.23	
HMP/ YOI EASTWOOD PARK	0.20	
HMP / YOI STYAL	0.18	

Be AWaRe - Antibiotics in categories Access . Watch . Reserve .


## Access 1st choice Narrow spectrum. Lower cost. Fewer side effects.

#### Watch 2nd choice

- Higher resistance potential.
- · Broader spectrum.
- Monitor use carefully.
- 1<sup>st</sup> or 2<sup>nd</sup> line indicated for limited number of infections.


#### Reserve Final option


- For use in patients with life threatening or multi-drug resistant bacteria.
- Monitor use very closely.
- Protect to ensure continued effectiveness.



The majority of the top 10 prescribed antibiotics are from the Access category, however, co-amoxiclav, lymecycline and clarithromycin from the watch category make up a significant proportion of antibiotic use, making these an area of focus.

## Acne antibiotics have had a recent uptick





### Course length improvements seen but more work to do:

% 5 day course amoxicillin 500mg
 Apr23- Mar24 28% to 41% Apr25- Sep25




% 5 day course doxycycline 100mg
 Apr23- Mar24 6% to 10% Apr25- Sep25





% 3 day course nitrofurantoin 100mg MR in women
 Apr23- Mar24 45% to 67% Apr25- Sep25




% 5 day course clarithromycin 12% Apr25-Sep25









#### World AMR Awareness Week in Health and Justice

#### November 2025



#### What's new for 2025 Globally:

World Health Organization's (WHO's) theme for the World AMR Awareness Week (WAAW) 2025 is "Act Now: Protect Our Present, Secure Our Future". This theme underscores the urgent need for bold, coordinated, cross-sectoral action to address AMR, a growing global threat that is already affecting our health, food systems, environment and economies.

The slogan of WAAW remains 'Antimicrobials: Handle with Care', WAAW campaign materials produced by WHO are available from their campaign website. Launched in May 2024, the World Health Organization's AMR is invisible. Lam not campaign puts advocates front and centre to share their stories, raise awareness and urge action to address AMR

In the UK, the daily themes have been updated for 2025:

Day 2 - 'Antimicrobials in clinical practice' theme

control measures and vaccination).

Day 3 - 'Optimising diagnostics' theme

Day 4-'Tackling health inequalities' theme

Day 5 - 'One Health and research' theme

Day 1 - 'Prevention' theme (including infection prevention and Children and young Sustainabil ity Research

Cross-cutting themes (all days)

Each theme is linked to at least one outcome in the 2024-29 National Action Plan (NAP) for AMR. The annual UKHSA WAAW/EAAD/AG Resource toolkit for healthcare professionals is available to download here. This provides a variety of resources useful for WAAW and for AMR/AMS activities throughout the year, including Andi-Biotic resources.

### Comms

- Antibiotic formulary pack- Nov24
- Newsletters to different healthcar-Nov24 professional groups
- Pharmacy AMS intervention flowchart-Nov24
- Inside-time magazine 'advert' published twice
- Prison radio
- Three meetings with LET via revolving doors
- Posters presented at RPS conference and UKHSA conference
- Antibiotic Guardian award highly commended in the health inequalities category
- WAAW newsletter 2025



## Next steps



NEW DATA DASHBOARD COMPLETION AND PROMOTION



ANTIBIOTIC SMRS FOR REPEAT ANTIBIOTICS



DEVELOP TRAINING PACKS AND POSTERS/LEAFLETS BASED ON LET

**FEEDBACK** 



SKINCARE RESEARCH PROJECT



ACNE IMPROVEMENT PLAN



**DENTAL QI PROJECT** 



BROAD SPECTRUM
IMPROVEMENT PROJECT



MOTIVATION INTERVENTION PROJECT FOR HCPS